TCL1A and leukemia: The adverse clinical outcomes in some solid tumors and leukemias in association with high TCL1A expression are likely to a considerable part the result of the TCL1A-mediated augmented activity of AKT contributing to enhanced proliferation and multi-nodal resistance [26,35,75,76].